Inspira Technologies partners with Bites for AI-powered training

RA’ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), a micro-cap medical device company with a market value of $32 million and showing a remarkable 91% price surge over the past six months, announced Wednesday a strategic collaboration with Bites Learning Ltd. to integrate AI-powered training capabilities into its medical device ecosystem. According to InvestingPro analysis, the company’s stock has demonstrated significant volatility with a beta of 2.3.

The partnership will embed Bites’ AI learning platform as a standard feature across Inspira’s product line, including future versions of the INSPIRA ART100 cardiopulmonary support system and HYLA blood sensor. With InvestingPro data showing an overall weak financial health score of 1.62, this strategic move could be crucial for the company’s growth trajectory. InvestingPro subscribers have access to 8 additional key insights about IINN’s financial position.

According to the press release, the integration aims to streamline training, accelerate onboarding, and enhance operational performance for hospitals and users of Inspira’s medical devices worldwide.

Key components of the collaboration include AI-driven training modules, interactive simulations, and digital maintenance guides. The system will also deliver personalized micro-content and compliance reminders to users.

"By integrating Bites’ AI engine directly into our ecosystem, we are transforming how medical teams learn, operate, and scale proficiency," said Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies.

Tal Nagler Almog, Chief Operating Officer of Bites, stated the platform will "empower Inspira’s global network with real-time, personalized knowledge delivery."

The collaboration framework includes provisions for evaluating future strategic transactions or deeper commercial integration between the companies.

Inspira Technologies develops respiratory support and blood monitoring solutions. Its INSPIRA ART100 system is FDA-cleared for cardiopulmonary bypass in the U.S. and for ECMO procedures outside the U.S.

Bites Learning Ltd. provides AI-based digital training and knowledge platforms using adaptive microlearning technology.

In other recent news, Inspira Technologies OXY B.H.N. Ltd. has received U.S. patent approval for its ART500 core technology, a low flow rates extracorporeal oxygenation system. The patent, which includes 16 novel claims, secures protection for the technology until at least 2043. Additionally, the company announced a significant $27 million purchase order from a national health ministry in Africa for its ART100 systems, with the deployment set to begin immediately and full payment expected by 2025. In other developments, Inspira Technologies has filed a routine shelf registration renewal with the U.S. Securities and Exchange Commission, a process conducted every three years. The company also engaged a specialized consulting firm to aid in its strategic expansion and partner engagement initiatives. This firm is known for working with biotech and medtech companies at critical growth stages, focusing on strategic transactions and commercial growth. These recent developments reflect Inspira Technologies’ ongoing efforts to enhance its market presence and technological offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.